Form 4: AnaptysBio Director Ware J. Anthony Acquires Stock Options and Restricted Stock Units

Director Ware J. Anthony of AnaptysBio, Inc. reports acquisition of stock options and restricted stock units (RSUs) on January 7, 2025.

Summary

• On January 7, 2025, J. Anthony Ware, a director of AnaptysBio, Inc., acquired stock options and restricted stock units.
• Ware acquired 16,510 stock options with an exercise price of $14.83.
• These options vest monthly, starting February 7, 2025, over a 12-month period, contingent on continued service to the company, and expire on January 6, 2035.
• Ware also acquired 6,030 restricted stock units (RSUs).
• These RSUs vest 100% on the date of the Issuer's 2026 annual meeting of shareholders, contingent on continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock options and RSU grants, which is generally a positive sign of aligning management interests with shareholders, but doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedules for both the stock options and RSUs incentivize the director to remain with the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the equity grants suggest an expectation of continued service and alignment with shareholder interests.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the biotechnology industry.
• Vesting schedules and exercise prices are typically structured to align executive incentives with long-term shareholder value creation.
• The specific terms of these grants (vesting period, exercise price) would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a positive sign of company stability and growth potential.

Key Dates